Page 102 - Flipbook

Interim results from a phase 1 study of

AMG 160, a half-life extended (HLE),

PSMA-targeted, bispecific T-cell engager

(BiTE ) immune therapy for metastatic
®
castration-resistant prostate

cancer (mCRPC)

Ben Tran, MBBS, FRACP, Lisa Horvath, PhD, MBBS, FRACP, Tanya Dorff,
1
2
MD, Matthew Rettig, MD, Martijn P. Lolkema, MD, PhD, Jean-Pascal Machiels,
5
4
3
MD, Sylvie Rottey, MD, PhD, Karen Autio, MD, Richard Greil, MD, Nabil Adra,
6
8
7
9
MD, MSc, Charlotte Lemech, MD, FRACP, Mukul Minocha, PhD, Fu-Chih
10
11
12
Cheng, PhD, Hosein Kouros-Mehr, MD, PhD, Karim Fizazi, MD, PhD 13
12
12
1 Peter MacCallum Cancer Centre, Melbourne, Australia; Chris O'Brien Lifehouse, Camperdown,
2
Australia; City of Hope, Duarte, CA, USA; University of California, Los Angeles, CA, USA; Erasmus MC
5
4
3
Cancer Institute, Rotterdam, Netherlands; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Drug
6
7
Research Unit, Ghent University, Ghent, Belgium; Memorial Sloan Kettering Cancer Center, New York, NY,
8
USA; Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT and Cancer
9
10
Cluster, Salzburg, Austria; Indiana University School of Medicine, Indianapolis, IN, USA; Scientia Clinical
11
12
13
Research, Randwick, Australia; Amgen Inc., Thousand Oaks, CA, USA; Gustave Roussy, University of
Paris Saclay, Villejuif, France